Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Threshold Pharmaceuticals has had an incredibly strong time in the market as of late, and for good reason. Investors are waiting on an update from the company with regard to its lead candidate. Today, we’ll talk about what investors are so excited about, what we’re seeing from the stock today, and what we can expect to see from THLD ahead.
Trade smarter and make more money with Tradespoon!
THLD One Day Closer To A Big Catalyst
Fr some time now, Threshold Pharmaceuticals has been working on a treatment known as Tarloxotinib. The treatment is designed to treat head and neck cancer as well as lung cancer (more specifically, non-small cell lung cancer). To do so, the treatment releases a substance that inhibits EGFR. As a result, the goal is to stop the replication and proliferation of cancerous cells in solid tumors. Of course, this is all in theory, as the company is working to prove the drug’s abilities through clinical studies.
The first clinical study THLD performed surrounding Tarloxotinib proved to be overwhelmingly positive. As a result, we are in the midst of the Phase 2 clinical trial for the treatment. As a matter of fact, Tarloxotinib is currently being studied for both the head and neck cancer indication as well as the lung cancer indication.
Perhaps more importantly, the data from the Phase 2 clinical studies will be released relatively soon. In fact, THLD said that it would be releasing this data at some point in September. So, we’re seeing massive spikes in the value of the stock as investors have a hard time holding back their excitement with regard to the coming release of data.
What We’re Seeing In The Market Today
As investors, one of the first things that we learn is that the news has the potential to move the market, even if the overall news hasn’t been released just yet. At the end of the day, clinical trials are overwhelmingly important to clinical stage biotechnology companies like Threshold Pharmaceuticals. Soon, the company will release data with regard to its most recent trials, and investors can’t wait to see the results. In the mean time, they are pushing the value of the stock upward with gains that are continuing in today’s trading session. Currently (10:37), THLD is trading at $1.33 per share after a gain of $0.12 per share (9.92%) thus far today.
What We Can Expect To See Moving Forward
Don’t waste your time! Click here to find winning trades in minutes!
Moving forward, I have an overwhelmingly bullish expectation of what we can expect to see from THLD. The bottom line is that the company is getting closer and closer to an approved treatment. The results that are expected later this month will likely push them even closer. Not to mention, there’s a ton of money in the indications that the company is working on tackling. If Tarloxotinib proves to be an effective treatment for either head and neck cancer or non-small cell lung cancer, incredible profits are likely to be seen. However, if the treatment proves to be effective in both indications, the sky really is the limit. All in all, I’m expecting to see further gains.
[Image Courtesy of Wikipedia]